VANCOUVER, BC , Aug. 15, 2023 /CNW/ - Mind Cure Health Inc. (the " Company " or " LNG Energy ") is pleased to announce that the Company has completed the previously announced business combination (the " Transaction ") with LNG Holdings Inc. (formerly LNG Energy Group Inc.) (" LNG Holdings ") by way of a court-approved plan of arrangement pursuant to an amended and restated arrangement agreement between the Company and LNG... Read More

VANCOUVER, BC , Aug. 4, 2023 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (" Mind Cure " or the " Company ") is pleased to announce that in connection with the Company's previously announced reverse takeover transaction (the " Proposed Transaction ") with LNG Holdings Inc. (formerly known as LNG Energy Group Inc.) (" LNG Energy "), LNG Energy closed its private placement of 44,577,350 subscription... Read More

Highlights: U.S. $70 million committed financing to complete the acquisition of Lewis Energy Colombia, Inc. The Transaction represents the first step in the creation of a Latin America energy platform. TORONTO , July 27, 2023 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTC: MCURF) (the " Company ") is pleased to announce that a wholly-owned subsidiary of LNG Holdings Inc. (formerly known as LNG Energy Group Inc.) ("LNG... Read More

TORONTO , June 9, 2023 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (the " Corporation " or " Mind Cure ") is pleased to announce that in connection with the Corporation's previously announced reverse takeover transaction (the " Proposed Transaction ") with LNG Energy Group Inc. (" LNG Energy "), LNG Energy closed the initial tranche of a private placement of 31,229,630 subscription receipts of LNG... Read More

VANCOUVER, BC , June 8, 2023 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (" Mind Cure ", the " Company " or the " Resulting Issuer " following the completion of the Proposed Transaction (as defined below)) and LNG Energy Group Inc. (" LNG Energy ") are pleased to provide an update on the previously announced arrangement agreement dated May 5, 2023 (the " Original Arrangement Agreement ") pursuant to... Read More

VANCOUVER, BC , May 11, 2023 /CNW/ - Mind Cure Health Inc. (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement of units (each, a " Unit ") at $0 .05 per Unit. The Company issued 2,500,000 Units for gross proceeds of $125,000 . Each Unit consists of one common share and one-half of one share... Read More

VANCOUVER, BC , May 5, 2023 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (" Mind Cure ", the " Company " or the " Resulting Issuer " following the completion of the Proposed Transaction (as defined below)) and LNG Energy Group Inc. (" LNG Energy ") are pleased to provide an update on the previously announced binding letter of intent dated November 17, 2022 . Effective as of the date hereof, Mind Cure... Read More

VANCOUVER, BC , April 20, 2023 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") today announced its financial results for the three and nine months ended February 28 , 2023. All amounts are stated in Canadian dollars unless otherwise indicated. A copy of the Company's financial statements for the three and nine months ended February 28, 2023 and the related management's... Read More

VANCOUVER, BC , Jan. 25, 2023 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") today announced its financial results for the three and six months ended November 30 , 2022. All amounts are stated in Canadian dollars unless otherwise indicated. A copy of the Company's financial statements for the three and six months ended November 30, 2022 and the related management's... Read More

VANCOUVER, BC , Nov. 18, 2022 /CNW/ - Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (" Mind Cure " or the " Company ") today announced that it has signed a binding Letter of Intent (the " LOI ") with LNG Energy Group Inc. (" LNG Energy ") pursuant to which the Company will acquire all of the issued and outstanding securities in the capital of LNG Energy by way of a business combination transaction (the "... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") today announced its financial results for the three months ended August 31 , 2022. All amounts are stated in Canadian dollars unless otherwise indicated. The special committee of the Company's board of directors is continuing to explore, review and evaluate a broad range of strategic alternatives with its strategic review process. The... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") today announced its financial results for the three and twelve months ended May 31 , 2022. All amounts are stated in Canadian dollars unless otherwise indicated. The special committee of the Company's board of directors is continuing to explore, review and evaluate a broad range of strategic alternatives with its strategic review... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") today announced its financial results for the three and nine months ended February 28 , 2022. All amounts are stated in Canadian dollars unless otherwise indicated. A copy of the Company's financial statements for the three and nine... Read More

Announces Executive and Employee Reductions and Cost Saving Measures Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), announced today that a special committee of the Company's board of directors (the "Special Committee") has concluded the initial phases of its previously announced... Read More

Provisional Patent Filed on Non-Racemic Ibogaine Mixtures Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today that it has developed a number of non-racemic mixtures of ibogaine... Read More

Independent Special Committee Formed Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today its Board of Directors has formed a special committee (the "Special Committee") of... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology for mental health care and research in psychedelics, announced today the hiring of Dr. Clare Purvis , formerly Headspace Inc.'s Vice President of Clinical Product and Content Development, for... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, today announced its financial results and operational highlights for the three and six months ended November 30 , 2021. All amounts are stated in Canadian dollars... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, today announced that President & Chief Executive Officer, Kelsey Ramsden , will present virtually at the H.C. Wainwright Bioconnect Conference taking place on... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, announced today that the Company and its digital therapeutics technology, iSTRYM, have been certified as Health Insurance Portability and Accountability Act... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, announces the appointment of Doron Sagman , MD, FRCPC, as the Company's new Chief Medical Officer ("CMO"). Dr. Joel Raskin who was acting CMO will transition into... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, today announced that President & Chief Executive Officer, Kelsey Ramsden , will present virtually at H.C. Wainwright's 2nd Annual Psychedelics Conference, the... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to provide an operational progress update on the strategic initiatives of its operating segments - MINDCURE Research and MINDCURE Technology. MINDCURE... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce the signing of a non-binding letter of intent ("LOI") with Awakn Life Sciences (NEO: AWKN)(OTCQB: AWKNF) ("Awakn"), a biotechnology company... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden , President & CEO of MINDCURE, will participate in two upcoming events in November 2021 : Wonderland Miami to be held in-person... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, today announced its financial results for the three months ended August 31 , 2021. All amounts are stated in Canadian dollars unless otherwise indicated. Q1... Read More

MINDCURE invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for... Read More

Reinforces MINDCURE's financial integrity and provides greater visibility to U.S. Investors Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, announced today that it has graduated from OTCQB Venture Market to now trade on the OTCQX Best Market (" OTCQX "), the highest tier of OTC Markets Group. MINDCURE begins... Read More

V Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden , President & CEO of MINDCURE, will present at the Benzinga Healthcare Small Cap Conference, which is being held virtually on September 29-30, 2021 . Investors can register for the conference here . In addition, Ms. Ramsden... Read More

First-of-its-kind study targets a female sexual disorder affecting an estimated 9.5 million women in the U.S. alone Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, introduces its "Desire Project," a clinical... Read More

MINDCURE to utilize patient data provided by ATMA to optimize iSTRYM, its digital therapeutics platform Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today an exclusive data licensing agreement with... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today it has been included in the new AdvisorShares Psychedelics ETF, trading on the NYSE Arca under the ticker symbol "PSIL" (the "ETF"). PSIL offers... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden , President & CEO of MINDCURE, will participate in two panel sessions at the Advances in Mental Health Virtual Conference,... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, announced today it's joining the Digital Therapeutics Alliance, a non-profit association of industry leaders with a mission to drive awareness and adoption of... Read More

As the official meeting of the Psychedelic Medicine Association, this conference will connect mental health professionals with promising research and breakthrough treatment therapies from the emerging field. Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced that Kelsey Ramsden , President & CEO of MINDCURE, will present at the H.C. Wainwright 23 rd Annual Global Investment Conference being held from... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research in psychedelics, today announced its financial results for the three and twelve months ended May 31, 2021 . All amounts are stated in Canadian dollars unless otherwise indicated.... Read More

With its minimum viable product (MVP) release on schedule and on budget, MINDCURE will work with its clinical partners to refine the application before full commercial deployment in Q1 2022. Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology... Read More

Dr. Weingardt, a clinical psychologist and previously a Senior Clinical Director at Pear Therapeutics will guide MINDCURE's digital therapeutics technology (DTx) platform, iSTRYM, through near-term commercial deployment Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in... Read More

The recipient of numerous human rights and leadership awards, Mr. White will assist MINDCURE on its mission to revolutionize mental health treatments through the development and scaling of science-backed psychedelic medicines globally. Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a... Read More

MINDCURE's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug. Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics,... Read More

The company's pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug, ibogaine. Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (" MINDCURE " or the "Company") , a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that the Company's board of directors (the "Board") has adopted a policy that requires advance notice to the Company with respect to... Read More

Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company"), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that Maxim Group analysts Jason McCarthy and Michael Okunewitch initiated coverage on MINDCURE. About Mind Cure Health Inc. MINDCURE is a... Read More

MINDCURE will distribute these protocols to therapists through iSTRYM, its digital therapeutics platform. This milestone in protocol development unlocks the company's protocol distribution platform in time for iSTRYM's clinical MVP launch in Q3 2021. Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or... Read More

By manufacturing ibogaine, MINDCURE's research team will have access to a predictable and standardized supply of synthetic ibogaine while ensuring consistent dosing and reliable results. Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ), a leader in advanced proprietary technology and... Read More

Dr. Raskin is a psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ), a leader in advanced proprietary technology for... Read More

Dr. Brownstein, an esteemed epidemiologist, researcher at Boston Children's Hospital and professor at Harvard Medical School , will assist on MINDCURE's digital technology, data optimization and patient data security within iSTRYM, its psychedelic digital therapeutics platform Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF)... Read More

MINDCURE is well-positioned to capitalize on its near-term revenue strategy, complete beta testing and launch of digital therapeutic tool iSTRYM and further its research into psychedelics Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a leader in advanced proprietary technology for... Read More

Breathwork has shown promise at both replicating the experience of psychedelics and helping patients to integrate psychedelic-assisted psychotherapy into their lives Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a leader in advanced proprietary technology for psychedelic therapy,... Read More

Mr. Wolfe has extensive capital markets and debt and equity financing experience; Ms. Chaikowsky, the COO at BMO Wealth Management, has significant expertise in corporate governance, human resources and operational risk management Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a... Read More

LUCID's technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a leader in advanced proprietary technology for... Read More

Mr. Herrera, Who Will Join The Company As Its Vice President Of Growth And Strategic Partnerships, Has 15+ Years Of Global Life Sciences Experience And Will Help To Drive MINDCURE's Commercial Focus And Strategic Partnerships Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a leader... Read More

Utilizing Speak Ai's technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a leader in advanced proprietary... Read More

ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The Approval Of Health Canada's Section 56(1) Exemption Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce a further strategic equity investment in ATMA... Read More

Company Now Is In Two High Growth Rate Global Markets With iSTRYM In The DTx Market, Projected To Reach $56 Billion By 2025 And The Global Psychedelic Market Projected To Reach Over $7.5 Billion By 2028 1 Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) an industry leader in advanced... Read More

The award-winning professor and psychology Ph.D. is an expert in translating psychological research and science into Artificial Intelligence backed real-world solutions Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a leader in advanced proprietary technology for psychedelic... Read More

An accomplished international operator, Mr. Lebbadi led the medical division for Johnson & Johnson and has successfully scaled several high-growth companies Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a leader in advanced proprietary technology for psychedelic therapy, is pleased... Read More

This approval is a key step forward in the development of the company's iSTRYM digital therapeutics platform Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has received unconditional... Read More

T his potential treatment opportunity was confirmed by the company's bioinformatics platform, PsyCollage Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a leader in developing technology to advance psychedelic-related treatments, is pleased to announce that the Company's... Read More

The Company expects to have ibogaine manufactured and in use for research by Q4. Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) a leader in advanced proprietary technology for psychedelic drug discovery, is pleased to announce that it has begun the first stage of manufacturing... Read More

The completed equity investment strengthens ties between MINDCURE and ATMA Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ), a leader in developing technology to advance psychedelic-related treatments, is pleased to announce the completion of its initial strategic equity investment of... Read More

The appointment further strengthens the Company's leadership position in the use of technology to develop psychedelic-related treatments "Mind Cure" or the "Company" ), a leader in developing technology to create psychedelic-related treatments, is pleased to announce the addition of Rob Hill to the Board of Directors. Mr. Hill brings over twenty years of senior leadership experience in capital markets, and specific domain... Read More

MINDCURE's first items in a line of original supplements, including Reishi Energy , Lion's Mane Focus , Turkey Tail Immunity , and Teen, available for purchase. Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) is pleased to announce the release of its original nootropic and adaptogen product offerings (the "Products" ). Items can now be ordered from the Company's website and are... Read More

Mind Cure Health Inc. (" Mind Cure " or the " Company ") (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) has been asked by OTC Markets Group Inc. (" OTC Markets ") to comment on recent promotional activity concerning its common shares traded on the OTCQB. On February 11, 2021 , OTC Markets sent the Company copies of two articles (the " Articles ") purportedly distributed by National Inflation Association (" NIA "). The Company was not... Read More

Celebrated neurologist, psychiatrist and plant-medicine expert Dr. Dan Engle brings years of understanding of psychedelic medicine into research with Mind Cure. Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "Mind Cure" or the "Company" ) is pleased to announce the engagement of Dr. Dan Engle as Mind Cure's Primary Investigator Consultant. Dr. Engle is Board Certified in Psychiatry and Neurology, with a... Read More

MINDCURE's PsyCollage tool to drive decision-making for drug lead optimization and assist in the discovery of target receptors. Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) is pleased to announce that it has completed beta testing of its proprietary bioinformatics platform PsyCollage , achieving its Q1 testing milestone. Bioinformatics is an interdisciplinary field that develops... Read More

Warrants will be listed for trading on CSE under the symbol "MCUR.WT", starting Feb. 11, 2021 . Mind Cure Health Inc . (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ( "MINDCURE" or the "Company" ) is pleased to announce that the Canadian Securities Exchange (CSE) has accepted for listing the 38,334,100 units issued pursuant to the Company's previously announced prospectus offering that closed Feb. 10, 2021 . Each warrant entitles... Read More

VANCOUVER, BC , Feb. 10, 2021 /CNW/ - Mind Cure Health Inc. ("Mind Cure" or the "Company") (CSE: MCUR), a mental health and wellness company with a mission to identify and develop products that ease suffering, increase productivity, and enhance mental health, is pleased to announce that it has closed its previously announced bought deal short form prospectus public offering (the "Offering") of units (the "Units") through a... Read More